Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. - Wikidata - awgldk - TriplyDB

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

http://www.wikidata.org/entity/Q33622711

about

Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening.Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors Characterization of species C human adenovirus serotype 6 (Ad6)The challenge for gene therapy: innate immune response to adenoviruses Effect of adenoviral delivery of prodynorphin gene on experimental inflammatory pain induced by formalin in rats Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers.Advances and future challenges in adenoviral vector pharmacology and targeting.Recent advances in oncolytic virus design.Manipulation of adenovirus interactions with host factors for gene therapy applications.Oncolytic virotherapy The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.Targeting Melanoma with Cancer-Killing Viruses.Oncolytic virotherapy: the questions and the promise.Imaging luciferase-expressing viruses.FX and host defense evasion tactics by adenovirus.Targeting adenoviruses with factor x-single-chain antibody fusion proteins Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5.

P2860

Q33645206-5F678311-4328-4BF7-BDE0-1DDFB49279D2 Q33906116-60D296B6-020E-4453-AF03-471D0B581A35 Q34153846-F399F76E-98D2-439B-BC50-AED1DF65EA0F Q34282191-9CAB89BD-F305-4207-A158-7EE233381C6A Q34669375-FA443BED-1ABF-433C-A44A-FA6E69D259A9 Q34975228-6C6BA751-0BBF-49DA-8E1F-873174078327 Q35016982-7D64C7BA-8BA6-4641-A649-F12A2D25CEA8 Q35096275-415E7F18-6D0A-4E27-974D-1066987A00FD Q35599319-26339986-10C3-47DC-B55B-292D5B9B36A9 Q36594178-761039B6-8AA5-459F-893F-24DEBF1290D4 Q37859842-520C572D-3762-45B7-B356-97CD5A7CE0DE Q37865172-6ADA2056-5593-4F94-B25E-FDEF12C712BF Q37984486-9F1D7B0B-38F0-4A3B-B559-FF620EF674B2 Q38025263-FFB5DDEE-7650-4EF0-95FD-D1E9469A5E9A Q38230901-C2A15A57-434E-4AD1-A4EE-30FA181253A7 Q38614156-576961A3-E080-4BCE-B48A-55631CF5D505 Q38676416-D09ECB9B-BEF5-4C68-A3AA-FCFAE9D5E128 Q38924527-A2C220E6-B345-463F-B242-E6954AE2F134 Q41832093-EAC3B23B-E6CB-4879-AF7C-BF9A46D77B8E Q42146790-AB6464B0-720E-4A83-BE01-EE4EAAAE3171 Q42533800-A041112E-DF6E-4DCE-90FE-B9C8190A6188 Q50851488-342E2360-816C-4CF6-BA64-583D177DB62D

P2860

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

http://www.wikidata.org/entity/Q33622711

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

@ast

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

@en

type

label

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

@ast

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

@en

prefLabel

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

@ast

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

@en

P1433

Q33622711-FC37EF90-B7E8-4729-903D-85772B178A24

P1476

Q33622711-15BE220E-934A-4697-A73A-9545604DACD3

P2093

Q33622711-13858A7C-312A-4BAF-AFF3-26E551A4F020

Q33622711-2EC3C4AC-6CBE-42E8-95AC-2BD2AB569737

Q33622711-455D5D9F-4570-483B-A652-63D428675873

Q33622711-45CF29CD-232D-4702-88F9-77C43199025F

P2860

Q33622711-023CEF36-F4F9-4322-A082-D7FD94D53A4F

Q33622711-05D44D8F-561D-4B19-AC22-07BBCD7967C1

Q33622711-0CA0D5F6-4CB5-4C22-8915-DD4E0ECC5588

Q33622711-0E3B78D4-6F53-4AE3-8F06-481305377468

Q33622711-12A462B4-89E3-4387-93E6-A0C7D66B0420

Q33622711-12BB6620-3674-42BA-A078-A153A6694848

Q33622711-12D570A3-AD19-40E3-BE51-F23C5E9491A4

Q33622711-1E209A3A-8376-4501-9266-1C004147B1BF

Q33622711-1F091FAD-EE86-43C3-93FB-05A4C44B224F

Q33622711-200B50F0-73E1-46E6-B598-0DD38298E000

P304

Q33622711-4C5F8076-7260-4769-A87E-F370D9864956

P31

Q33622711-37BC3128-043D-4FCA-A3D7-355513D7DD86

P356

Q33622711-BCBAA59B-CCC5-4D4C-BB8E-5FD2C7ECABD3

P433

Q33622711-054B0014-D14D-426C-87CA-FBAB06CA0091

P478

Q33622711-D6175D72-BB9C-48D3-9C42-EA9DFEC58D46

P577

Q33622711-FE591B74-C1E1-4A69-ABEE-DCB0B4E3AAED

P5875

Q33622711-E73B9D32-BA24-4740-808E-832FF48B1542

P698

Q33622711-5C3B89BF-9523-46AC-839E-5B991DB5BF10

P921

Q33622711-E7985F29-8CA3-4A64-9EB8-1D176AA8D001

Q33622711-F6EF696D-6057-49B7-9DBB-B27039C880AC

P932

Q33622711-5BEB8F1E-92A8-4E1C-87A6-51B14788802B

P356

P1433

Molecular Therapy

P1476

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

@en

P2093

Elena V Shashkova

http://www.w3.org/2001/XMLSchema#string

Konstantin Doronin

http://www.w3.org/2001/XMLSchema#string

Michael A Barry

http://www.w3.org/2001/XMLSchema#string

Shannon M May

http://www.w3.org/2001/XMLSchema#string

P2860

Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity

Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination.

Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons.

Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus

Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.

Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver.

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.

Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement

Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

P304

2121-2130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.217

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26813775

http://www.w3.org/2001/XMLSchema#string

P698

19755961

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2814381

http://www.w3.org/2001/XMLSchema#string